Technetium Tc 99m Sestamibi
Technetium Tc 99m Sestamibi Uses, Dosage, Side Effects, Food Interaction and all others data.
Technetium Tc 99m Sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands, hence the name sesta (6) MIBI.. Following intravenous injection of the drug, Technetium Tc 99m Sestamibi is taken up by the myocardium, parathyroid, and/or breast tissue. The mechanism by which sestamibi localizes to these tissues has not been established. Single photon emission computed tomography (SPECT) is then performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.
Currently available within a preparation kit for injection, Technetium Tc 99m Sestamibi is indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in patient management decisions.
| Trade Name | Technetium Tc 99m Sestamibi |
| Generic | Technetium Tc-99m sestamibi |
| Technetium Tc-99m sestamibi Other Names | 99m Tc-sestamibi, 99m-Tc sestamibi, 99mTc sestamibi, 99mTc-sestamibi, Sestamibi, Technetium (99m Tc) sestamibi, Technetium (99mTc) sestamibi, Technetium Tc 99m sestamibi |
| Type | |
| Formula | C36H66N6O6Tc |
| Weight | Average: 775.96 Monoisotopic: 775.5 |
| Protein binding | There is less than 1% protein binding of Technetium Tc 99m Sestamibi in plasma. |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Technetium Tc 99m Sestamibi is a radiopharmaceutical diagnostic agent used in nuclear medicine imaging tests to detect coronary artery disease and evaluate myocardial function.
Technetium Tc 99m Sestamibi is indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in patient management decisions.
Technetium Tc 99m Sestamibi is also used to associated treatment for these conditions: Coronary Artery Disease (CAD)
Toxicity
The following adverse reactions have been reported in > 0.5% of patients: signs and symptoms consistent with seizure occurring shortly after administration of the agent; transient arthritis; angioedema, arrhythmia, dizziness, syncope, abdominal pain, vomiting, and severe hypersensitivity characterized by dyspnea, hypotension, bradycardia, asthenia, and vomiting within two hours after a second injection of Technetium Tc 99m Sestamibi. A few cases of flushing, edema, injection site inflammation, dry mouth, fever, pruritis, rash, urticaria and fatigue have also been attributed to administration of the agent.
Food Interaction
No interactions found.Elimination Route
At five minutes post injection about 8% of the injected dose remains in circulation. Myocardial uptake which is coronary flow dependent is 1.2% of the injected dose at rest and 1.5% of the injected dose at exercise.
Half Life
Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours. Blood clearance studies indicate that the fast clearing component clears with a t½ of 4.3 minutes at rest, and clears with a t½ of 1.6 minutes under exercise conditions. The myocardial biological half-life is approximately six hours after a rest or exercise injection. The biological half-life for the liver is approximately 30 minutes after a rest or exercise injection.
Clearance
The effective half-life of clearance (which includes both the biological half-life and radionuclide decay) for the heart is approximately 3 hours, and for the liver is approximately 30 minutes, after a rest or exercise injection.
Elimination Route
The major pathway for clearance of Tc 99m Sestamibi is the hepatobiliary system. Activity from the gall bladder appears in the intestines within one hour of injection. Twenty-seven percent of the injected dose is excreted in the urine, and approximately thirty-three percent of the injected dose is cleared through the feces in 48 hours.
Innovators Monograph
You find simplified version here Technetium Tc 99m Sestamibi
